Fulgent Genetics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue declined due to a major customer transition, but acquisitions and new product launches are expected to drive growth. Guidance for 2026 is reaffirmed, with improved margins and reduced customer concentration risk anticipated.
Fiscal Year 2025
-
Revenue grew 14% in 2025 to $322.7 million, driven by innovation in AI and digital pathology, but 2026 will see a major customer loss offset by acquisitions and new product launches. Gross margins will dip early in 2026 but are expected to recover as integration and organic growth accelerate.
-
Consistent organic growth, technology-driven efficiency, and a robust cash position support ongoing expansion in diagnostics and therapeutics. Key catalysts include new product launches, AI integration, and upcoming clinical milestones in oncology.
-
Revenue and margins exceeded expectations, with strong growth in precision diagnostics and biopharma services. Technology integration, digital pathology, and AI are driving operational gains, while expanded managed care contracts and new product launches position the business for continued growth. M&A and therapeutics development remain strategic priorities.
-
Q3 2025 saw sequential and year-over-year growth, with revenue reaching $84.1 million and improved margins. Full-year guidance was raised, driven by strong performance in precision diagnostics, new product launches, and progress in the therapeutic pipeline.
-
Q2 2025 saw strong sequential and year-over-year growth in core revenue, margin improvement, and raised full-year guidance. Key drivers included expanded managed care coverage, new genomic services, and progress in the therapeutic pipeline.
-
Year-over-year growth achieved across all business lines, with strong momentum in precision diagnostics and biopharma services. 2025 guidance maintained, projecting 10% core revenue growth and robust cash reserves, while investments in digital pathology and therapeutic development continue.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong core revenue growth, margin improvement, and successful new product launches. 2025 guidance anticipates 10% core revenue growth, continued investment in sales and R&D, and a robust cash position to support strategic initiatives.
-
Operations are anchored in laboratory services and drug development, with strong 2024 revenue guidance and improved gross margins. Recent NIPT launch and industry consolidation drive growth, while robust technology and a strong cash position support ongoing expansion and acquisitions.
-
Strong Q3 growth was driven by expanded test offerings, operational improvements, and new contracts, including a major VA award. The business is investing in sales and innovation, with a robust pharma pipeline and improved margins. Investor communication will focus on clarifying the dual diagnostics and drug development strategy.
-
Q3 2024 saw $71.7M revenue, strong growth in core lab services, and a $99M VA contract win. Non-GAAP gross margin hit 40%, and full-year guidance was raised for EPS and core revenue. Cash remains robust at $815M, supporting future M&A and growth.
-
Q2 2024 saw strong core revenue growth, margin improvement, and operational gains across all business segments, with precision diagnostics and reproductive health leading. Guidance for 2024 core revenue and margins was reiterated, and the company maintains a robust cash position to support growth and strategic initiatives.